The price of an exosome add-on is built from five parts: the exosome material and its format, the extra time in the session, the base procedure it is paired with, the storage and documentation behind each lot, and the practitioner’s time and training. The base procedure, whether microneedling, RF microneedling or a fractional laser, usually sets the frame, and the add-on sits on top of it.
We found no peer-reviewed study or government source that sets a US price benchmark for an exosome add-on, and the one peer-reviewed price survey we found was global and spanned many uses, so this guide quotes no figure. It explains each part of the price instead, shows why two practices can quote very different numbers for what sounds like the same visit, and ends with the questions that make a quote easy to compare.
Where the FDA stands
The FDA stated in its 2019 public safety notification, and again in a 2024 consumer alert, that there are no FDA-approved exosome products. The agency’s microneedling page states that microneedling devices are not approved for delivering cosmetics, topical medications or other products into the skin. ExaVeyra supplies exosome material for topical aesthetic use by licensed practitioners, and each practitioner decides whether and how to use it.
Understanding why no published US price benchmark exists yet
Aesthetic add-ons are priced practice by practice, and very few practices publish their prices. Asadpour and colleagues surveyed the websites of 114 businesses offering secretome, vesicle or exosome services in 28 countries between July and November 2022, and reported in 2023 that only 38 listed any price at all.
That survey is the closest published source on pricing, and it was never designed to give a US benchmark. It covered many countries and many uses, and the authors reported that prices for cosmetic uses sat at the low end of the range they found, with the lowest listed price, for skin care, offered by a US business, while noting that, to their knowledge, none of the services were covered by insurance.
Without a published benchmark, any single number in an online article is one practice’s price on one day. Understanding what goes into the price is the more reliable way to judge a quote.
Understanding the five components of an exosome add-on price
Each part of the price reflects a real cost that sits with the supplier, the device maker or the practice. The table sets out what each covers and the published source that describes it.
| Component | What it covers | What shapes it | Where it is described |
|---|---|---|---|
| Exosome material and format | The product applied after the procedure, sometimes with take-home product | Cell source, manufacturing method, vial size and formulation | Staubach 2021; Borger 2026; Rahman 2025; Kwon 2020 |
| Session time | The extra minutes to thaw or prepare the material and apply it | Whether the step is folded into the procedure visit or booked separately | Park GH 2023; Estupiñan 2025 |
| Base procedure | Microneedling, RF microneedling or a fractional laser before the topical step | The device, its consumables such as a new needle cartridge, and the number of sessions | FDA microneedling page; FDA 510(k) K231790; Kumar 2026 |
| Storage and documentation | Frozen shipping and storage, lot records and the certificate of analysis | Cold-chain requirements and the characterization behind each lot | Ahmadian 2024; Görgens 2022; MISEV2023 |
| Practitioner time and training | Consultation, the procedure itself and follow-up | The provider’s training on the device and the local market | FDA RF microneedling safety communication; Shaffrey 2023 |
Material and format costs reflect how the vesicles are made
Exosome material is made in stages. Staubach and colleagues described in 2021 how vesicle production runs from cell banking and expansion, through the collection of conditioned media, to clarification, concentration, purification and quality control, and they noted that most laboratory isolation methods are limited in how far they scale.
The cell source changes that cost. Borger and colleagues reported in 2026, in a laboratory study using rat material, that vesicles isolated from plasma were obtained with lower cost and less labor time than vesicles from cultured adipose stromal cells, an example of how the starting material can change the production cost.
Products also differ in what they contain. Rahman and colleagues analyzed 70 formulations from 18 manufacturers in 2025 and reported that growth factor concentrations varied significantly across human, plant and animal sources, and Knauer and colleagues reported in 2026 that commercial products carried minimal information on isolation, processing or shelf life, so a lower material price may describe a different product altogether.
Format matters too. Vial size, how the material is formulated and whether the protocol includes take-home product all change the material line; in the Kwon 2020 study, participants applied the same gel at home on the two days after each laser session.
The base procedure sets most of the price frame
An exosome add-on is almost always paired with a procedure that makes small channels in the skin first. The published session designs used microneedling in Park GH 2023, RF microneedling in Estupiñan 2025 and a fractional CO2 laser in Kwon 2020, and each device carries its own cost for the equipment, the consumables and the provider’s time.
Consumables are a real line item. The FDA advises patients to ask whether a new microneedle cartridge is used for each patient and for each session, and a practice that follows that advice builds a fresh cartridge into every visit.
Understanding microneedling with exosomes cost
Microneedling is usually the simplest base procedure, so the add-on can be a larger share of the visit price. Park GH and colleagues ran three microneedling sessions three weeks apart in a 2023 split-face study of 28 adults, and a series priced on that pattern multiplies both the procedure and the material by three.
Understanding Morpheus8 with exosomes price
Morpheus8 is an RF microneedling system; the FDA’s 510(k) database lists the InMode System with the Morpheus8 Applicators (K231790) under the electrosurgical cutting and coagulation device classification. An RF microneedling session involves a capital device, consumable needle tips and more provider time, so the base procedure usually makes up most of the visit price.
We found no published study and no registered trial pairing Morpheus8 specifically with exosome material in searches of PubMed and ClinicalTrials.gov on 9 November 2026. The closest published design, Estupiñan 2025, used a different RF microneedling device with three sessions four weeks apart, and Kumar and colleagues reviewed 20 RF microneedling studies in 2026 and reported that side effects were mostly mild and short-lived.
Understanding exosome facial cost
An exosome facial is usually described as a cleanse, a procedure step and the topical exosome step in one visit. Its price depends mostly on which procedure step the practice uses, so asking which device will be used is the quickest way to compare two quotes for an exosome facial.
Storage and documentation are part of every lot
Vesicle material is sensitive to how it is stored, and keeping it cold is a cost from the manufacturer to the practice freezer. Ahmadian and colleagues reviewed 50 storage studies in 2024 and reported that constant subzero storage, optimally at minus 80 degrees Celsius, preserved vesicle quantity and cargo, while repeated freeze-thaw cycles reduced particle concentration and RNA content.
Formulation plays a part as well. Görgens and colleagues reported in 2022 that storage buffer and temperature changed how well vesicles held up, with plain buffer reducing recovery within days, so a product designed to stay stable carries that development cost.
Documentation is the other half of the line. The MISEV2023 guideline from the International Society for Extracellular Vesicles sets out characterization by size, concentration, marker proteins and appearance under a microscope, and a certificate of analysis that follows those headings takes laboratory work for every lot.
ExaVeyra exosome material ships frozen from the manufacturing facility on dry ice, in every available format. Each lot carries its lot number, and a certificate of analysis is generated for every lot and is available on request, together with the characterization panel and the cold-chain records; every ExaVeyra certificate reports serological testing for pathogens, and miRNA characterization data is available to qualifying accounts on request.
Why exosome add-on prices vary between practices
Prices for the same named service differ for reasons that have little to do with the exosome material. Shaffrey and colleagues analyzed 66 practices that published cosmetic surgery prices online, compared them with US national averages, and reported in 2023 significant price differences by region for most procedures; their study concerned surgery, and similar market forces may shape the price of an aesthetic add-on.
Bundling is the second reason. In the same analysis, every practice included the surgeon’s fee in its published price, but only 38 included a facility fee and 34 an anesthesia fee, so two quotes can differ simply because one includes more.
- Region and market: Shaffrey 2023 reported significant regional differences in published cosmetic surgery prices, and local costs and demand may shape aesthetic pricing in a similar way.
- Base device: a microneedling pen, an RF microneedling system and a fractional laser carry very different equipment and consumable costs.
- Product: source, manufacturing and formulation differ between products, as Rahman 2025 and Knauer 2026 reported.
- Series length: the published designs cited here each used three sessions, so a per-visit price and a series price are not comparable.
- What is bundled: numbing cream, standardized photos, take-home product and follow-up visits may or may not be in the quote.
- Provider: the FDA asks patients to choose a licensed provider with training and experience on RF microneedling devices, and that training is part of the cost of the visit.
Weighing value against the current evidence
Whether an add-on is worth its price is a decision for each person and their own licensed provider, and the evidence they weigh is early. Gaebe and colleagues reviewed 16 studies with 503 participants in 2026 and reported that most found improvement in at least one skin measure with no serious adverse events, while rating the certainty of the evidence low or very low.
The individual studies point in more than one direction. Park GH and colleagues reported higher appearance scores on the exosome side than the saline side after microneedling in 2023, while Estupiñan and colleagues reported in 2025 that exosomes and PRP after RF microneedling improved the two halves of the face equally.
No published study we found compares the cost of a procedure with an exosome add-on against the procedure alone. Value therefore rests on the evidence for the specific product, the documentation behind it and the provider’s explanation of both.
Understanding what the evidence does not yet show
- No US benchmark: we found no government source that publishes a US price for an exosome add-on, and the one peer-reviewed price survey we found was a global website snapshot from 2022 that spans many uses.
- No cost comparison: no published study we found compares the cost of a session with and without the exosome step.
- Small studies: the controlled studies cited here enrolled 15 to 28 people, and Wang, Bajwa and Rivers reported in 2026 that small samples and single-arm designs limit the field.
- Different products: Knauer 2026 reported minimal information on isolation, processing or shelf life across the products surveyed, so a study of one product may not apply to another.
- Industry ties: the Kwon 2020 gels were provided by their manufacturer, Estupiñan 2025 was supported in part by a grant from the company that made both the exosome products and the RF microneedling device used, and two authors of the Kumar 2026 review work for a device maker.
- No Morpheus8 pairing data: no published study or registered trial pairing that device with exosome material was found on 9 November 2026.
Each of these gaps is a clear opportunity for larger, better documented studies. Clear records at the practice level make every future comparison easier.
Questions to ask about what the price includes
A good quote answers these questions without hesitation. Each one follows from a study or an FDA page cited in this guide.
- Is the price for one visit or a series, and how many sessions does the series include?
- Which base procedure and which device will be used, and is the device FDA-cleared?
- Will a new needle cartridge or tip be opened for my session, as the FDA advises patients to ask?
- Which exosome product will be applied, who makes it, and what cells does it come from?
- Can I see the lot number, and is the certificate of analysis for that lot available on request?
- How is the product shipped and stored before my visit?
- Are numbing cream, photos, take-home product and follow-up visits included in the price?
- What training does the provider have on this device, and who do I contact with a concern?
Documenting the add-on in the practice record
A practice that records the add-on clearly can explain its price in a sentence. The record that does this lists the base device and cartridge, the exosome product and lot number, the storage log, and where the certificate of analysis and characterization panel are filed.
- Base procedure: device name, 510(k) number where applicable, and a note that a new cartridge or tip was opened.
- Exosome material: product name, available format, lot number and the date the lot was received frozen.
- Storage: freezer temperature log and any thaw event, following the handling evidence in Ahmadian 2024.
- Documents: certificate of analysis, characterization panel and cold-chain records for the lot, requested from the supplier and filed.
- Pricing: what the quoted price includes, so the next quote for the same service matches it.
Looking ahead with clearer prices and better records
Exosome add-ons are young, and clearer product documentation, larger studies and more open pricing would each make quotes easier to compare. Practices that explain each part of the price and keep the lot records to back it up give patients a simple reason to trust the quote.
Morpheus8 and any other product or device names in this guide or its references are trademarks of their respective owners. ExaVeyra supplies exosome material to licensed practitioners, shipped frozen from the manufacturing facility with lot documentation available on request, so the material line of every quote can be explained. Practices with a question about a product, a certificate or a documentation requirement are welcome to ask the scientific team directly, and anyone can apply for a free account without an NPI; NPI verification then unlocks the practitioner portal, exclusive resources and pricing.
Aviso Educativo: This article is for educational purposes only and does not constitute medical or legal advice. It does not identify any material, compound, device setting or protocol as safe, effective or appropriate for any patient, and it is not intended to diagnose, treat, cure, or prevent any disease. Questions about a treatment belong with the reader’s own licensed provider. Exosome material is supplied for topical aesthetic use by licensed practitioners. No exosome product is FDA-approved for any use, and ExaVeyra Sciences makes no statement about administration, route, or outcome. Compounded medications are not FDA-approved. They are prepared by a 503A compounding pharmacy licensed by the Texas State Board of Pharmacy for an individual patient against that patient’s prescription, and are available to NPI-verified licensed practitioners only, in the states where the pharmacy is licensed. Product, device and brand names mentioned are trademarks of their respective owners and are used only to identify the products discussed. Their mention is not an endorsement, and those owners have not reviewed or endorsed this article. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. Findings described are attributed to the peer-reviewed literature, trial registries and agencies cited. The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.
Referencias
- 1.Gaebe K, Lowe K, Bosnalie D, Khoury S, Villemure Poliquin N, Nichols A. Effectiveness and Safety of Extracellular Vesicle-Based Therapies for Nonsurgical Facial Rejuvenation: A Systematic Review. Facial Plast Surg Aesthet Med. 2026. Published online ahead of print. PMID 42487416. doi:10.1177/26893614261457879PRISMA systematic review with risk-of-bias and GRADE assessment; 16 studies, 503 participants. Carries in this article: most included studies reported improvement in at least one skin measure with no serious adverse events, while the authors rated certainty low or very low, which frames the value question. Disclosure: academic authors (Canada); no COI statement in the PubMed record.
- 2.Knauer G, Chang A, Gupta A, Brownstone N, Mejia N, Bauman S, et al. Clinical Evidence and Commercial Landscape of Topical Exosomes for Skin Rejuvenation: A Scoping Review. Aesthet Surg J. 2026;46(11):NP148-NP157. PMID 42411735. doi:10.1093/asj/sjag141Scoping review (2,394 records screened, 18 human studies) plus a survey of the first 20 commercial products in a Google Shopping search. Carries in this article: the products surveyed carried minimal information on isolation, processing or shelf life, so the price of one product says little about another. Disclosure: academic authors (USA); no COI statement in the PubMed record.
- 3.Wang OJE, Bajwa BB, Rivers JK. Exosome-Based Therapies in Dermatology: A Scoping Review. J Drugs Dermatol. 2026;25(4):368-376. PMID 41931695. doi:10.36849/jdd.9610Scoping review (PRISMA-ScR) including trial registries; 17 human studies from 2020 to 2025. Carries in this article: the authors reported that small samples, single-arm designs and potential conflicts of interest limit the evidence. Disclosure: no COI statement in the PubMed record.
- 4.Rahman E, Sayed K, Rao P, Abu-Farsakh H, Sadeghi-Esfahlani S, Garcia PE, et al. Exosome Revolution or Marketing Mirage? AI-Based Multi-domain Evaluation of Claims, Scientific Evidence, Transparency, Public Sentiment, and Media Narratives. Aesthetic Plast Surg. 2025;49(12):3454-3479. PMID 40055226. doi:10.1007/s00266-025-04712-3Multi-domain analysis of 18 manufacturers and 70 product formulations, with social media, media articles and consumer reviews analyzed by automated methods (level of evidence V). Carries in this article: high transparency was found in 18% of manufacturers, and growth factor concentrations varied significantly across human, plant and animal sources, the reason the material line differs between products. Disclosure: the authors declared no conflict of interest.
- 5.Asadpour A, Yahaya BH, Bicknell K, Cottrell GS, Widera D. Uncovering the gray zone: mapping the global landscape of direct-to-consumer businesses offering interventions based on secretomes, extracellular vesicles, and exosomes. Stem Cell Res Ther. 2023;14(1):111. PMID 37138298. PMC10156419. doi:10.1186/s13287-023-03335-2Cross-sectional survey of business websites searched July to November 2022; 114 businesses in 28 countries, 34 of them in the USA. Carries in this article: only 38 of the 114 listed any price, the authors reported that pricing for cosmetic uses sat at the low end of the range they found, with the lowest listed price (skin care) offered in the USA, and they wrote that, to their knowledge, none of the services were covered by insurance. The survey is global and spans many uses, so it gives no US benchmark for an aesthetic add-on. Disclosure: the authors declared no competing interests.
- 6.Shaffrey EC, Wirth PJ, Moura SP, Attaluri PK, Rao VK. The Price Is Right? An Economic Analysis of Factors Influencing Cosmetic Surgery Prices. Aesthet Surg J. 2023;43(9):1036-1045. PMID 36947151. doi:10.1093/asj/sjad072Cross-sectional analysis of 66 practices that published cosmetic surgery prices online, compared with The Aesthetic Society national databank averages. Carries in this article: an analogy for why aesthetic prices differ, since published prices differed significantly by region for most procedures and practices bundled different components (surgeon fee in all 66, facility fee in 38, anesthesia fee in 34). It concerns surgery, not exosome add-ons. Disclosure: no COI statement in the PubMed record; academic authors.
- 7.Park GH, Kwon HH, Seok J, Yang SH, Lee J, Park BC, et al. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: A 12-week prospective, randomized, split-face study. J Cosmet Dermatol. 2023;22(12):3418-3426. PMID 37377400. doi:10.1111/jocd.15872Prospective, randomized, split-face study; three microneedling sessions three weeks apart with saline on the control side; adults (Korea); n = 28. Carries in this article: the microneedling session design that a microneedling-with-exosomes price is built around, and the reported gains on the exosome side with no serious adverse events observed. Disclosure: the PubMed record lists government research grants and no COI statement.
- 8.Kwon HH, Yang SH, Lee J, Park BC, Park KY, Jung JY, et al. Combination Treatment with Human Adipose Tissue Stem Cell-derived Exosomes and Fractional CO2 Laser for Acne Scars: A 12-week Prospective, Double-blind, Randomized, Split-face Study. Acta Derm Venereol. 2020;100(18):adv00310. PMID 33073298. PMC9309822. doi:10.2340/00015555-3666Prospective, double-blind, randomized, split-face study; three fractional CO2 laser sessions three weeks apart; adults (Korea); n = 25. Carries in this article: a laser-based session design, with gel applied after the laser and again at home on the next two days, so the material line can include take-home product. Disclosure: the exosome and control solutions were manufactured, purified and provided by the exosome manufacturer (full text acknowledgements); the authors declared no conflicts of interest.
- 9.Estupiñan B, Ly K, Goldberg DJ. Adipose Mesenchymal Stem Cell-Derived Exosomes Versus Platelet-Rich Plasma Treatment for Photoaged Facial Skin: An Investigator-Blinded, Split-Face, Non-Inferiority Trial. J Cosmet Dermatol. 2025;24(5):e70208. PMID 40414798. PMC12104007. doi:10.1111/jocd.70208Investigator-blinded, split-face, non-inferiority trial; three full-face RF microneedling sessions at 4-week intervals, a 30-minute topical anesthetic step, topical exosomes on one half and PRP on the other; adults (USA); n = 15. Carries in this article: an RF microneedling session design, and the reported equal improvement of the two arms, which bears on the value question. Disclosure: supported in part by a research grant from the company that the full text names as the maker of both the exosome products and the RF microneedling device used; the authors declared no conflicts of interest.
- 10.Kumar N, Suh DH, Lee SJ, Kasif SA, Carruthers JDA. Radiofrequency Microneedling for Facial Rejuvenation: A Systematic Review. J Cosmet Dermatol. 2026;25(4):e70845. PMID 41947517. PMC13058395. doi:10.1111/jocd.70845PRISMA and JBI systematic review with GRADE-CERQual; 20 studies, 558 participants. Carries in this article: RF microneedling as the base procedure behind a Morpheus8-with-exosomes price, with adverse events in the reviewed studies reported as mostly mild and short-lived. Disclosure: two authors work for, and one speaks for, an RF microneedling device maker.
- 11.Staubach S, Bauer FN, Tertel T, Börger V, Stambouli O, Salzig D, Giebel B. Scaled preparation of extracellular vesicles from conditioned media. Adv Drug Deliv Rev. 2021;177:113940. PMID 34419502. doi:10.1016/j.addr.2021.113940Narrative review of upstream processing (cell banking, expansion, conditioned media), downstream processing (clarification, volume reduction, purification) and quality control for vesicle products. Carries in this article: the manufacturing steps that sit behind the material line, and the authors’ point that common laboratory isolation methods are limited in scalability. Disclosure: the authors declared no competing interests.
- 12.Borger A, Haertinger M, Millesi F, Semmler L, Supper P, Stadlmayr S, et al. Comparison of Plasma- and Adipose Tissue-Derived Stromal Cell Extracellular Vesicles for Schwann Cell Proliferation and Cost-Effectiveness. Plast Reconstr Surg. 2026. Published online ahead of print. PMID 42695774. doi:10.1097/PRS.0000000000013410Laboratory study in rat material comparing vesicles isolated from plasma with vesicles from cultured adipose stromal cells, including a cost and working-hours analysis of each preparation. Carries in this article: the authors reported that plasma-derived vesicles were obtained with lower cost and less labor time than vesicles from cell culture, an example of how source changes production cost. Animal material, not a commercial product. Disclosure: the authors declared no conflicts of interest.
- 13.Ahmadian S, Jafari N, Tamadon A, Ghaffarzadeh A, Rahbarghazi R, Mahdipour M. Different storage and freezing protocols for extracellular vesicles: a systematic review. Stem Cell Res Ther. 2024;15(1):453. PMID 39593194. PMC11600612. doi:10.1186/s13287-024-04005-7Systematic review of 50 original studies on storage temperature, freezing technique, freeze-thaw cycles and stabilizers. Carries in this article: rapid freezing and constant subzero storage (optimally minus 80 degrees Celsius) preserved vesicle quantity and cargo, while repeated freeze-thaw cycles reduced particle concentration and RNA content, the reason cold-chain handling is part of the price. Disclosure: one author was employed by a private research and development company; the others declared no competing interests.
- 14.Görgens A, Corso G, Hagey DW, Jawad Wiklander R, Gustafsson MO, Felldin U, et al. Identification of storage conditions stabilizing extracellular vesicles preparations. J Extracell Vesicles. 2022;11(6):e12238. PMID 35716060. PMC9206228. doi:10.1002/jev2.12238Laboratory stability study over up to 2 years across buffers and temperatures. Carries in this article: storage buffer and temperature changed how well vesicles held up, with plain buffer reducing recovery within days, so formulation and storage choices carry a cost. Disclosure: several authors list affiliation with a vesicle therapeutics company.
- 15.Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al; MISEV Consortium; Théry C, Witwer KW. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. PMID 38326288. PMC10850029. doi:10.1002/jev2.12404International Society for Extracellular Vesicles reporting guideline. Carries in this article: the characterization headings (size, concentration, marker proteins, morphology) that a certificate of analysis can follow, which is the documentation work behind a lot. Disclosure: many consortium authors list vesicle company affiliations, declared in the article.
- 16.U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. December 6, 2019 (content current as of 12/06/2019; verified 9 November 2026). https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-productsAgency safety notification (CBER). Carries in this article: the agency statement that there are currently no FDA-approved exosome products, and its request that adverse events be reported through MedWatch.
- 17.U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. Content current as of 04/09/2024; verified 9 November 2026. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomesAgency consumer alert (CBER). Carries in this article: the FDA restates that exosome products are regulated by the agency and that there are no FDA-approved exosome products, and points readers to MedWatch.
- 18.U.S. Food and Drug Administration. Microneedling Devices. Content current as of 10/15/2025; verified 9 November 2026. https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/microneedling-devicesAgency device information page (CDRH). Carries in this article: the statement that microneedling devices are not approved for delivering cosmetics, topical medications or other products into the skin; the advice to ask whether a new needle cartridge is used for each patient and each session, a consumable in the price; and the advice to ask about provider training.
- 19.U.S. Food and Drug Administration. Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling: FDA Safety Communication. Date issued October 15, 2025; verified 9 November 2026. https://www.fda.gov/medical-devices/safety-communications/potential-risks-certain-uses-radiofrequency-rf-microneedling-fda-safety-communicationAgency safety communication (CDRH). Carries in this article: the FDA describes RF microneedling as a medical procedure and asks patients to seek a licensed provider with training and experience on the device and to ask which device will be used, the practitioner-time line of the price.
- 20.U.S. Food and Drug Administration. 510(k) Premarket Notification K231790: The InMode System with the Morpheus8 Applicators (InMode Ltd.). Decision date July 20, 2023; product code GEI, regulation 21 CFR 878.4400. Verified 9 November 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K231790FDA 510(k) database record. Carries in this article: Morpheus8 applicators were found substantially equivalent under the electrosurgical cutting and coagulation device classification, so a Morpheus8 session is a device procedure whose cost sits under any exosome add-on. The record states a device classification and makes no statement about exosomes or topical products.